how cute, it can read and write/type. Take a look at the FierceBiotech article from today. It states that all biotech CEO's want to talk about is deals. It's Let's make a deal in biotech land. Even if Hep C is a failure, Factor D could make ACHN worth $BB's in 1-2 years and of course they have $400MM in cash in the bank to fund development all the way.
See the article, it's let's make a deal time in biotech land. It would be nice if the long overdue data was available. Let's get something done for the shareholders ARNA BOD and execs.
Immunogen was working on a similar target FOLR1 I think they called it. In fact, I alerted them to the ECYT folate test. I understand the target and how ADC's like Kadcyla work. So far, no one has developed a SMDC and ECYT's failed. Good luck with ECYT, I just don't think SMDC's are going to deliver enough payload to the target.
XNCR looks like a much more interesting Oncology clinical dev stage co to me, but I'm just getting started researching them.
I'm not aware of milestone payments and until/unless JNJ announce progress it's unlikely any will be achieved. Maybe something small with the start of the next phase of testing? Since ACHN rarely updates the shareholders and does not do quarterly cc's who knows???
Interesting, just today I read a Bloomberg report that stated Allergan is searching for deals after the Pfizer deal to acquire them fell through. Munshi and friends should be aware and in fact I just sent the article to them. There is no shortage of large pharma and biotech firms searching for M&A, licensing deals, pipeline expansion...just look at XNCR's deal announced yesterday, that was huge.
This stock/company is slowly heading toward $0. Shareholders should demand they send the cash and close the company before they waste it all. They seem to have nothing of value except maybe the diagnostic tool. I wasted years following, investing and trading IMGN, but it seems ADC's are a flop and I never understood how SMDC's were going to deliver the payload. I have no position, but if I did it would not be long. All IMO, not advice.
rare diseases have different rules, you should know that. Try again, make something else up, spew some more FUD, or just cover and come back in again at $10+ in a few weeks or months.
not true, ACHN is planning as if launch will be in 2018. Give them a call and check this claim out. I know it sounds aggressive, but they believe they can move this forward very rapidly. We shall see.
it appears the initial phase II done by ARNA for REM was positive and then the phase IIB in REM was not positive based on the 2 links I followed from the IV board??? Any ideas on what happened?
looks like some of the research reported on this drug is for REM sleep, not the new indications AXON is seeking is old and from ARNA, not new and from AXON. Oops, we will have to wait to hear about Lewy Body...
I have most of the posters who responded to this on ignore, jackshat, amadyf, arenakicked...
3 replies, all ignored, must have struck a chord with shortie? Don't you think it's time to cover and exit?
BTW, RGLS, another potential competitor bit the dust. Of course GILD is the main target/competitor and a very strong one. FD is my focus, not Hep C. We need updates!!!
I sent this today, Why ARNA shareholders are ANGRY...
Stock price performance and valuation vs. a peer group.
We need cost cuts and licensing deals to extend the runway and we need them yesterday! Stop wasting the shareholder money on 250 employees that can't add to the valuation of the company (at this point). R&D seems to have developed some potentially great compounds, but ARNA's executive management and BOD have managed to burn the cash and destroy shareholder value. The shareholders paid the price, now everyone needs to share in the pain and the shareholders (OWNERS) demand a focus on ROI, not further dilution.
ARNA is valued at $400MM and $1.65 stock price thanks to low-priced dilution and poor business decision-making
AXON is worth $1.1 BB (3x)
GWPH=1.94 BB (5x)